Mounjaro vs Ozempic vs Zepbound vs Wegovy (2026): The Honest Comparison

If you're choosing between these four medications — or wondering whether to switch — this is the piece you want. Not the manufacturer-branded comparison. Not the affiliate-driven "top 5" listicle. A data-grounded, clinically-honest look at where each drug wins, where each loses, and who should probably be on which one.

We've broken it down across eight dimensions: efficacy, indication, side effects, dosing, cost, insurance, availability, and the one most comparisons skip — what they actually feel like week to week on a dose.

The One-Paragraph Summary

Mounjaro and Zepbound are the same drug (tirzepatide), just labeled differently — Mounjaro for type 2 diabetes, Zepbound for weight management. Similarly, Ozempic and Wegovy are the same drug (semaglutide) — Ozempic for diabetes, Wegovy for weight. So functionally you have a two-drug choice: semaglutide vs tirzepatide. Tirzepatide produces more weight loss on average (~20% vs ~15%), costs more, has similar side effect profiles, and works on an additional hormone receptor. Semaglutide has a longer safety track record, broader insurance coverage, and is the better starting point for most diabetes-focused treatment.

The Four Drugs, in Plain Language

Drug	Active ingredient	FDA Label	Drug Class
Ozempic (Novo Nordisk)	Semaglutide	Type 2 diabetes	GLP-1 receptor agonist
Wegovy (Novo Nordisk)	Semaglutide	Weight management	GLP-1 receptor agonist
Mounjaro (Eli Lilly)	Tirzepatide	Type 2 diabetes	GLP-1/GIP dual agonist
Zepbound (Eli Lilly)	Tirzepatide	Weight management	GLP-1/GIP dual agonist

Three things matter from this table:

1. The drugs pair up — Ozempic = Wegovy mechanistically, Mounjaro = Zepbound mechanistically
2. Tirzepatide works on TWO hormone pathways (GLP-1 and GIP); semaglutide on ONE
3. The weight-management labels (Wegovy, Zepbound) go higher in max dose than the diabetes labels (Ozempic, Mounjaro)

Efficacy: what each pivotal trial found (separate trials)

Weight loss averages from pivotal clinical trials, in patients with obesity but without type 2 diabetes:

Drug	Avg weight loss	Trial	Duration
Wegovy (semaglutide 2.4mg)	~14.9%	STEP-1	68 weeks
Zepbound (tirzepatide 15mg)	~20.9%	SURMOUNT-1	72 weeks
Wegovy HD (semaglutide 7.2mg, 2026)	18.7% (20.7% among people who stayed on treatment)*	STEP UP	72 weeks

*Wegovy HD (higher dose) is newer and narrows the gap against tirzepatide somewhat.

The honest framing: on average, tirzepatide outperforms semaglutide for weight loss by ~5-6 percentage points. That's not small — it's the difference between a 15% and a 21% total body weight reduction. But individual response varies enormously. Some people lose more on semaglutide than they would have on tirzepatide.

For blood sugar (A1C) reduction in type 2 diabetes:

Drug	A1C reduction	Trial
Ozempic (1mg)	~1.5%	SUSTAIN-6
Mounjaro (15mg)	~2.1-2.3%	SURPASS-2

Mounjaro wins on diabetes efficacy too, though Ozempic's track record is longer.

Head-to-Head: Side Effects

The profiles are surprisingly similar — both drug classes hit the GI tract hardest. Incidences from the pivotal trials:

Side Effect	Ozempic/Wegovy	Mounjaro/Zepbound
Nausea	20-45%	25-33%
Diarrhea	8-30%	18-23%
Constipation	5-24%	7-16%
Vomiting	5-24%	10-13%
Headache	Common	Common
Fatigue	Common	Common

Important nuance: the 20-45% range for Ozempic/Wegovy nausea reflects how studies were run — higher ranges come from rapid-titration protocols. In the real world with slower titration, most people sit in the lower half of these ranges.

The most common serious side effects are the same across both classes:

• Pancreatitis (rare, ~0.1-0.2%)
• Gallbladder issues (uncommon, rate increases with rapid weight loss)
• Kidney issues (mostly related to dehydration from severe GI effects)
• Risk of medullary thyroid carcinoma in people with specific genetic predispositions (contraindication)

Neither drug class is clearly "safer." For most healthy adults, they are comparably tolerable with similar peaks during dose escalation.

For a month-by-month timeline on tirzepatide side effects specifically, see our Zepbound timeline. For nausea management on either drug, see 8 remedies that actually work.

Head-to-Head: Dosing

Both drug classes are once-weekly subcutaneous injections. The titration schedules are different:

Semaglutide (Ozempic/Wegovy): 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg (Wegovy max) Ozempic tops at 2mg. Each step is typically 4 weeks.

Tirzepatide (Mounjaro/Zepbound): 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg (max) Each step is typically 4 weeks minimum. 15mg is the max for both indications.

Practical implications:

• Tirzepatide has more gradual increments — finer control over titration
• Semaglutide reaches max dose in ~20 weeks; tirzepatide in ~20-24 weeks
• Both start intentionally subtherapeutic — the first dose is for tolerance, not weight loss

Head-to-Head: Cost (2026)

List prices without insurance, per month:

Drug	Monthly cost (no insurance)	With savings card	With insurance (typical)
Ozempic	$900-1,000	$25-150 (if diabetic, commercial insurance)	$0-100 copay
Wegovy	$1,350	$25 (eligibility-based)	$25-300 copay (if covered)
Mounjaro	$1,112 (US list, Lilly, Oct 2026)	$25-150 (if diabetic, commercial insurance)	$0-100 copay
Zepbound	up to $1,086 (US list, Lilly, Oct 2026)	$25 with coverage; $299–$449 without (KwikPen or vials, refills within 45 days; otherwise $499–$699)	$25-300 copay (if covered)

Two 2026 developments that matter:

1. Generic competition is coming — authorized generics of semaglutide started appearing in 2025-2026, pushing prices down. Generic tirzepatide isn't here yet.
2. Foundayo (orforglipron) launched in April 2026. Lilly's US self-pay price is $149 a month for the lowest doses, $199 for 5.5 mg and $299 a month for the higher doses (with refills within 45 days); its list price is $649 for 30 days (Lilly, October 2026).

If cost is your decision driver, Ozempic or Wegovy are usually cheaper, and Wegovy has broader savings-card eligibility than Zepbound in practice.

Head-to-Head: Insurance Coverage

This is where it gets messy. Coverage varies by plan, employer, and state:

• Diabetes indications (Ozempic, Mounjaro): Widely covered by commercial insurance if you have a T2D diagnosis. Medicare Part D usually covers.
• Weight management indications (Wegovy, Zepbound): Very uneven. Many commercial plans exclude weight-loss drugs entirely. Medicare covers Wegovy for cardiovascular risk reduction as of 2024-2025. Medicaid coverage varies by state.

Practical rule: if you have T2D, you'll almost certainly get Ozempic or Mounjaro covered. If you're using the drug for weight management alone, prepare for a prior authorization battle or out-of-pocket costs.

Head-to-Head: Availability

The 2024-2025 shortage period has largely stabilized by April 2026, but pockets remain:

Drug	Availability status (as of April 2026)
Ozempic	Stable. All doses available.
Wegovy	Stable. All doses available.
Mounjaro	Generally stable. Occasional 12.5/15mg backorders.
Zepbound	Generally stable. Vial-based lower doses intermittent.

Compounded GLP-1 drugs (which appeared during the shortage) are now heavily restricted — the FDA issued warning letters to dozens of telehealth companies in February 2026. If you're getting compounded semaglutide or tirzepatide, read our GLP-1 source safety piece.

Head-to-Head: The Lived Experience

Clinical trials measure outcomes. Here's what actual GLP-1 users report across the four drugs, based on pooled data from pilot programs and community forums:

Ozempic / Wegovy:

• Appetite suppression onset: 5-10 days from first injection
• Food noise quieting: typically 2-4 weeks
• Energy: generally stable; some fatigue at escalation
• "Taste fatigue" for greasy/sweet foods: commonly reported
• Alcohol tolerance: often dramatically reduced
• Emotional response: more reports of mood flattening at higher doses

Mounjaro / Zepbound:

• Appetite suppression onset: 3-7 days — often faster perceived
• Food noise quieting: typically 2-3 weeks
• Energy: most people report similar or better than semaglutide
• Cravings: stronger specific reduction in sweet/sugar cravings (GIP receptor?)
• "Feels stronger" is a common descriptor in weeks 2-6

This isn't clinical fact — it's aggregated subjective reporting. But it tracks with what clinicians anecdotally say: tirzepatide "feels" more assertive, semaglutide "feels" more subtle.

Which One for Whom?

Choose Ozempic or Mounjaro if:

• You have type 2 diabetes
• Insurance coverage is the deciding factor
• You want a drug with a longer track record (Ozempic specifically)

Choose Wegovy or Zepbound if:

• Weight management is the primary goal
• You've confirmed insurance coverage or can afford out-of-pocket
• You want access to the higher weight-loss doses

Lean semaglutide (Ozempic/Wegovy) if:

• You're risk-averse about newer drugs
• Cost matters and generic competition is imminent
• You've tolerated other Novo Nordisk drugs before
• You want broader Medicare/Medicaid options

Lean tirzepatide (Mounjaro/Zepbound) if:

• Maximum weight loss is the priority
• You have significant obesity (BMI >35)
• Your diabetes is poorly controlled on other agents
• You didn't respond well to semaglutide

What to Ask Your Prescriber

1. "Based on my history, which of these drugs is most likely to work for me?"
2. "What's my out-of-pocket cost with my current insurance for each option?"
3. "If the first drug doesn't work, how do we decide whether to switch or escalate dose?"
4. "Am I at elevated risk for any of the more serious side effects?"
5. "What's your typical titration schedule? Can we slow it down if I don't tolerate the first few weeks?"

The Bigger Truth

Both drug classes are transformative for the right person. The differences between them are real but often smaller than people assume — what matters more is how well the drug fits your biology, your insurance, your goals, and the behavioral work you're willing to do around the medication.

And that last part is the one no comparison article talks about. A 15% weight loss on semaglutide that you maintain through habits beats a 21% weight loss on tirzepatide that regresses after you stop. The drug is a tool. The life around it is the engine.

For what happens after any of these drugs — what makes results stick — see building habits that outlast your GLP-1 prescription.

---

Frequently Asked Questions

Is Mounjaro the same as Zepbound? Yes. Both are tirzepatide — the same active ingredient, same manufacturer (Eli Lilly), different brand names for different FDA-approved indications (Mounjaro for diabetes, Zepbound for weight management).

Is Ozempic the same as Wegovy? Yes. Both are semaglutide from Novo Nordisk. Ozempic is labeled for type 2 diabetes (max dose 2mg). Wegovy is labeled for weight management (max dose 2.4mg, or 7.2mg with the 2026 Wegovy HD approval).

Which produces more weight loss — semaglutide or tirzepatide? In SURMOUNT-5, the head-to-head trial, tirzepatide averaged 20.2% weight loss at 72 weeks and semaglutide 13.7% — 6.5 percentage points apart. Individual response varies widely.

Can I switch from Ozempic to Mounjaro? Yes, and this is a common path for people who don't respond well to semaglutide. Your prescriber will typically restart titration at the lowest tirzepatide dose (2.5mg) rather than dose-match.

Which has fewer side effects? They're comparable. Tirzepatide may produce slightly higher nausea incidence in trials, but also allows finer dose titration, which can offset that. Individual tolerability matters more than class averages.

Which is cheaper — Ozempic or Mounjaro? Ozempic is typically slightly cheaper at list price ($900-1,000 vs $1,112/month; Mounjaro per Lilly's US list price, October 2026) and has longer-standing commercial insurance coverage for diabetes. With manufacturer savings cards, prices can be similar. Generic semaglutide is beginning to appear, which will shift this picture significantly.

---

Matt Cole is a research co-host of the Gila podcast. This article draws from the STEP-1, STEP UP, SUSTAIN-6, SURMOUNT-1, and SURPASS-2 trials, FDA-approved prescribing information for all four drugs, and 2026 pricing data from GoodRx and manufacturer savings programs.